[1] A. Mebazaa, M.S. Nieminen, M. Packer, et al., Levosimendan vs dobutamine for pa- tients with acute decompensated heart failure: the SURVIVE randomized trial, Jama. 297 (2007) 1883–1891.
[2] M. Nikolaou, J. Parissis, M.B. Yilmaz, et al., Liver function abnormalities, clinical pro- file, and outcome in acute decompensated heart failure, Eur. Heart J. 34 (2013) 742–749.
[3] V.M. van Deursen, K. Damman, H.L. Hillege, A.P. van Beek, D.J. van Veldhuisen, A.A. Voors, Abnormal liver function in relation to hemodynamic profile in heart failure patients, J. Card. Fail. 16 (2010) 84–90.
[4] S. Moller, M. Bernardi, Interactions of the heart and the liver, Eur. Heart J. 34 (2013) 2804–2811.
[5] L.A. Allen, G.M. Felker, S. Pocock, et al., Liver function abnormalities and outcome in patients with chronic heart failure: data from the candesartan in heart failure: as- sessment of reduction in mortality and morbidity (CHARM) program, Eur. J. Heart Fail. 11 (2009) 170–177.
[6] H.J. Eisen, The MELD scoring system and the prediction of outcomes in heart failure patients: what we have learned from the hepatologists, J. Am. Coll. Cardiol. 61 (2013) 2262–2263.
[7] T. Inohara, S. Kohsaka, Y. Shiraishi, et al., Prognostic impact of renal and hepatic dys- function based on the MELD-XI score in patients with acute heart failure, Int. J. Cardiol. 176 (2014) 571–573.
[8] S. Abe, A. Yoshihisa, M. Takiguchi, et al., Liver dysfunction assessed by model for end-stage liver disease excluding INR (MELD-XI) scoring system predicts adverse prognosis in heart failure, PLoS One 9 (2014), e100618, .
[9] J. Biegus, R. Zymlinski, M. Sokolski, et al., Impaired hepato-renal function defined by the MELD XI score as prognosticator in acute heart failure, Eur. J. Heart Fail. 18 (2016) 1518–1521.
[10] A. Vallet-Pichard, V. Mallet, B. Nalpas, et al., FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and fibrotest, Hepatology. 46 (2007) 32–36.
[11] A.G. Shah, A. Lydecker, K. Murray, B.N. Tetri, M.J. Contos, A.J. Sanyal, Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease, Clin. Gastroenterol. Hepatol. 7 (2009) 1104–1112.
[12] H.J. Park, J.Y. Park, S.M. Jung, J.J. Song, Y.B. Park, S.W. Lee, Fibrosis-4 index at diagno- sis is associated with all-cause mortality in patients with microscopic polyangiitis and granulomatosis with polyangiitis, BMC Gastroenterol. 19 (2019) 90.
[13] S.U. Kim, B.K. Kim, J.Y. Park, et al., Fibrosis-4 index at diagnosis can predict all-cause mortality in patients with rheumatoid arthritis: a retrospective monocentric study, Mod. Rheumatol. 30 (2020) 70–77.
[14] Y. Sato, A. Yoshihisa, Y. Kanno, et al., Liver stiffness assessed by Fibrosis-4 index pre- dicts mortality in patients with heart failure, Open Heart. 4 (2017), e000598, .
[15] P.A. McKee, W.P. Castelli, P.M. McNamara, W.B. Kannel, The natural history of con- gestive heart failure: the Framingham study, N. Engl. J. Med. 285 (1971) 1441–1446.
[16] M.D. Samsky, C.B. Patel, T.A. DeWald, et al., Cardiohepatic interactions in heart fail- ure: an overview and clinical implications, J. Am. Coll. Cardiol. 61 (2013) 2397–2405.
[17] M. Jessup, M.R. Costanzo, The cardiorenal syndrome: do we need a change of strat- egy or a change of tactics? J. Am. Coll. Cardiol. 53 (2009) 597–599.
[18] O. Havakuk, K.S. King, L. Grazette, et al., Heart failure-induced brain injury, J. Am. Coll. Cardiol. 69 (2017) 1609–1616.
[19] W. Doehner, D. Ural, K.G. Haeusler, et al., Heart and brain interaction in patients with heart failure: overview and proposal for a taxonomy. A position paper from the study group on heart and brain interaction of the heart failure association, Eur. J. Heart Fail. 20 (2018) 199–215.
[20] J.E. Naschitz, D. Yeshurun, J. Shahar, Cardiogenic hepatorenal syndrome, Angiology. 41 (1990) 893–900.
[21] O. Sîrbu, M. Floria, P. Dascalita, et al., Anemia in heart failure - from guidelines to controversies and challenges, Anatol J Cardiol. 20 (2018) 52–59.
[22] V.P. Harjola, W. Mullens, M. Banaszewski, et al., Organ dysfunction, injury and fail- ure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the acute heart failure Committee of the Heart Failure Associa- tion (HFA) of the European Society of Cardiology (ESC), Eur. J. Heart Fail. 19 (2017) 821–836.
[23] J.E. Naschitz, G. Slobodin, R.J. Lewis, E. Zuckerman, D. Yeshurun, Heart diseases af- fecting the liver and liver diseases affecting the heart, Am. Heart J. 140 (2000) 111–120.
[24] R.K. Seeto, B. Fenn, D.C. Rockey, Ischemic hepatitis: clinical presentation and patho- genesis, Am. J. Med. 109 (2000) 109–113.
[25] A.P. Ambrosy, M. Vaduganathan, M.D. Huffman, et al., Clinical course and predictive value of liver function tests in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST trial, Eur. J. Heart Fail. 14 (2012) 302–311.
[26] V.M. van Deursen, C. Edwards, G. Cotter, et al., Liver function, in-hospital, and post- discharge clinical outcome in patients with acute heart failure-results from the re- laxin for the treatment of patients with acute heart failure study, J. Card. Fail. 20 (2014) 407–413.
[27] J. Henrion, Hypoxic hepatitis, Liver Int. 32 (2012) 1039–1052.
[28] C. Denis, C. De Kerguennec, J. Bernuau, F. Beauvais, Solal A. Cohen, Acute hypoxic hepatitis (’liver shock’): still a frequently overlooked cardiological diagnosis, Eur. J. Heart Fail. 6 (2004) 561–565.
[29] O.A. Trowell, The experimental production of watery vacuolation of the liver, J. Physiol. 105 (1946) 268–297.
[30] R. Birrer, Y. Takuda, T. Takara, Hypoxic hepatopathy: pathophysiology and progno- sis, Intern. Med. 46 (2007) 1063–1070.
[31] S. Yamaguchi, M. Abe, T. Arakaki, O. Arasaki, M. Shimabukuro, Incremental prognos- tic value of platelet count in patients with acute heart failure - a retrospective obser- vational study, Circ. J. 83 (2019) 576–583.
[32] J.M. Raurich, J.A. Llompart-Pou, M. Ferreruela, et al., Hypoxic hepatitis in critically ill patients: incidence, etiology and risk factors for mortality, J. Anesth. 25 (2011) 50–56.
[33] R.M. Taylor, S. Tujios, K. Jinjuvadia, et al., Short and long-term outcomes in patients with acute liver failure due to ischemic hepatitis, Dig. Dis. Sci. 57 (2012) 777–785.
[34] P.E. Hickman, J.M. Potter, Mortality associated with ischaemic hepatitis, Aust. NZ J. Med. 20 (1990) 32–34.
[35] O. Chioncel, A. Mebazaa, A.P. Maggioni, et al., Acute heart failure congestion and per- fusion status - impact of the clinical classification on in-hospital and long-term out- comes; insights from the ESC-EORP-HFA heart failure long-term registry, Eur. J. Heart Fail. 21 (2019) 1338–1352.
[36] M. Scholfield, M.B. Schabath, M. Guglin, Longitudinal trends, hemodynamic profiles, and prognostic value of abnormal liver function tests in patients with acute decom- pensated heart failure: an analysis of the ESCAPE trial, J. Card. Fail. 20 (2014) 476–484.
[37] G.T. Lau, H.C. Tan, L. Kritharides, Type of liver dysfunction in heart failure and its re- lation to the severity of tricuspid regurgitation, Am. J. Cardiol. 90 (2002) 1405–1409.
[38] V.M. van Deursen, K. Damman, P. van der Meer, et al., Co-morbidities in heart fail- ure, Heart Fail. Rev. 19 (2014) 163–172.
[39] P.J. Johnson, S. Berhane, C. Kagebayashi, et al., Assessment of liver function in pa- tients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade, J. Clin. Oncol. 33 (2015) 550–558.
[40] A. Okada, Y. Sugano, T. Nagai, et al., Usefulness of the direct and/or Total bilirubin to predict adverse outcomes in patients with acute decompensated heart failure, Am. J. Cardiol. 119 (2017) 2035–2041.
[41] R.K. Sterling, E. Lissen, N. Clumeck, et al., Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection, Hepatology. 43 (2006) 1317–1325.
[42] Y. Saito, Y. Okumura, K. Nagashima, et al., Impact of the Fibrosis-4 index on risk stratification of cardiovascular events and mortality in patients with atrial fibrilla- tion: findings from a Japanese multicenter registry, J. Clin. Med. 9 (2020).
[43] P. Bettencourt, P. Rodrigues, H. Moreira, P. Marques, P. Lourenco, Long-term progno- sis after acute heart failure: a differential impact of age in different age strata, J. Cardiovasc. Med. (Hagerstown) 18 (2017) 845–850.